Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Chronopharmacology of hydrocortisone and 9α-fluorhydrocortisone in the treatment for congenital adrenal hyperplasia

  • 49 Accesses

  • 26 Citations

Abstract

The conventional treatment of CAH with hydrocortisone (16–19 mg/m2 per day) and 9α-F-cortisol (just enough to normalise renin concentrations, started at 07:00 h) was inffective in suppressing the early morning rise of 17-OH-progesterone and in turn androgens in about 20% of our patients. The present work explored the effect of a modified dosage regimen of the drug in five patients. The schedule was: 03:00 h F 33%+9α-F-F 33%; 07:00 h F 30%; 12:00 h F 22%+9α-F-F 33%; 17:30 h F 15%+9α-F-F 33%.

Monitored levels of circulating 17-OH-progesterone, testosterone, and individual urinary 17-ketosteroids showed significant improvement, which was not achieved by giving higher or later evening doses. Menarche was induced in two girls (bone age 15 years). The modified dosage schedule offers on the one hand the possibility of better management of CAH, and on the other, cuts down the risk of enhanced Cushing-like effects, which in animal models have been related frequently to dosage schedules not corresponding to the circadian rhythm. The difficulty of administering the drugs at 03:00 h should be overcome by the development of a late-releasing preparation.

This is a preview of subscription content, log in to check access.

Abbreviations

CAH:

congenital adrenal hyperplasia

References

  1. 1.

    Gallagher TF, Yoshida K, Roffward HD, Fukushima DK, Weitzmann ED, Hellman L (1973) ACTH and cortisol secretory patterns in man. J Clin Endocrinol Metab 36:1053–1063

  2. 2.

    Gupta D (1970) A longitudinal study of the urinary excretion of individual steroids in children during adolescent growth. Steroidologica 1:267–294

  3. 3.

    Krieger DT (1979) Rhythms in CRF, ACTH and corticosteroids. In: Krieger DT (ed) Comprehensive endocrinology. Raven Press, New York, pp 123–142

  4. 4.

    Nieschlag E, Wenner H, Bren H, Wickings EJ, Schelling G (1980) Adrenogenitales Syndrom. Therapeutische Einstellung anhand des Tagesprofils des 17-Hydroxyprogesterons im Serum. Dtsch Med Wochenschr 105:600–603

  5. 5.

    New MI, Levine LS (1984) Steroid 21-hydroxylase deficiency. In: New MJ, Levine LS (eds) Adrenal diseases in childhood. Karger, Basel, pp 1–46

  6. 6.

    Smith R, Donald RA, Espiner EA, Glatthaar Ch, Abbott G, Scandrett M (1980) The effect of different treatment regimens on hormonal profiles in congenital adrenal hyperplasia. J Clin Endocrinol Metab 51:230–236

  7. 7.

    Smolensky MH, Halberg F, Pitts GC, Nelson W (1980) The chronopharmacology of methylprednisolone: clinical implications of animal studies with special emphasis upon the moderation of growth inhibition by timing to circadian rhythms. In: Smolensky MH, Reinberg A (eds) Recent advances in the chronobiology of allergy and immunoloy. Elmsford, New York, pp 137–171

  8. 8.

    Winterer J, Chrousos GP, Loriaux DL, Cutler GB Jr (1985) Effect of hydrocortisone schedule on adrenal steroid secretion. J Pediatr 106:137–142

Download references

Author information

Correspondence to H. Moeller.

Additional information

This work was presented in part on the 80th Annual Meeting of the Deutsche Gesellschaft für Kinderheilkunde, September 16–19, 1984, in Tübingen

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moeller, H. Chronopharmacology of hydrocortisone and 9α-fluorhydrocortisone in the treatment for congenital adrenal hyperplasia. Eur J Pediatr 144, 370–373 (1985). https://doi.org/10.1007/BF00441780

Download citation

Key words

  • Chronopharmacology
  • Congenital adrenal hyperplasia
  • Hydrocortisone
  • 9α-Fluorhydrocortisone
  • Treatment